DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention…
BERKELEY HEIGHTS, N.J., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the…
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while…
BEIJING, Dec. 23, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…
PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec.…
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on…
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved…
Needle-Free Growth Hormone Support via Telehealth — Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume…
Analysis Examines GlucoBooster GLP-1 Gummies and Akkermansia-Based Probiotic Category Ahead of 2026 Weight-Loss Season – Ingredient Research, Regulatory Context, and…
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical…